Oncology Medical News about overall survival;lymphopenia;prognostic factor;advanced carcinomas;sarcomas;lymphomas

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
Cancer Research, 07/07/09

Ray-Coquard I et al. - In a trial to determine the effect of lymphopenia on relapse and survival in advanced carcinomas, sarcomas, and lymphomas, it was suggested that lymphopenia is an independent prognostic factor for overall (OS) and progression-free survival in several cancers.

Methods

Lymphopenia's prognostic value for survival was analyzed in 3 databases of previously reported prospective multicenter studies: FEC chemotherapy in metastatic breast carcinoma; CYVADIC in advanced soft tissue sarcoma; and prospective, consecutive phase III studies of aggressive diffuse large-cell non–Hodgkin's lymphomas.
Univariate and multivariate analyses of prognostic factors for survival were performed.

Results

Incidence of lymphopenia of <1000/μL before treatment was constant among the series: 25%, 24%, and 27%, respectively.
Lymphopenia was significantly more frequent in metastatic breast cancer pts with performance status (PS) of >1, non–Hodgkin's lymphoma pts with international prognostic index (IPI) of >0, and advanced soft tissue sarcoma and metastatic breast cancer pts with bone metastases.
In univariate analysis, lymphopenia of <1000/μL significantly correlated to OS in pts with metastatic breast cancer, advanced soft tissue sarcoma, and non–Hodgkin lymphoma.
Lymphopenia was an independent prognostic factor for OS in metastatic breast cancer along with liver metastases and PS; in advanced soft tissue sarcoma along with liver metastases, lung metastases, and PS; and in non–Hodgkin's lymphoma along with IPI.

<< Previous
Discontinuance of bacille Calmette-Guerin instillation therapy...

Next >>
Antitumor activity of gemcitabine and oxaliplatin is augmented by...